2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea
Chan Joo Lee, Minjae Yoon, Hyun‐Jae Kang, Byung Jin Kim, Sung Hee Choi, In‐Kyung Jeong, Sang‐Hak Lee, on behalf of Task Force Team for Familial Hypercholesterolemia, Korean Society of Lipid and Atherosclerosis
Abstract
. Proper suspicion of individuals with typical characteristics is essential for screening. Cascade screening is known to be the most efficient diagnostic approach. Early initiation of lipid-lowering therapy and the control of other risk factors are important. The first-line pharmacological treatment is statins, followed by ezetimibe, and PCSK9 inhibitors as required. The ideal treatment targets are 50% reduction and <70 mg/dL or <55 mg/dL (in the presence of vascular disease) of LDL-C, although less strict targets are frequently used. Homozygous FH is characterized by untreated LDL-C >500 mg/dL, xanthoma since childhood, and family history. In children, the diagnosis is made with criteria, including items largely similar to those of adults. In women, lipid-lowering agents need to be discontinued before conception.